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Although the diagnosis of Graves’ orbitopathy is primarily made clinically based on laboratory tests indicative of
thyroid dysfunction and autoimmunity, imaging studies, such as computed tomography, magnetic resonance
imaging, ultrasound and color Doppler imaging, play an important role both in the diagnosis and follow-up after
clinical or surgical treatment of the disease. Imaging studies can be used to evaluate morphological abnormalities of
the orbital structures during the diagnostic workup when a differential diagnosis versus other orbital diseases is
needed. Imagingmay also be useful to distinguish the inflammatory early stage from the inactive stage of the disease.
Finally, imaging studies can be of great help in identifying patients prone to develop dysthyroid optic neuropathy and
therefore enabling the timely diagnosis and treatment of the condition, avoiding permanent visual loss. In this paper,
we review the imaging modalities that aid in the diagnosis and management of Graves’ orbitopathy, with special
emphasis on the diagnosis of optic nerve dysfunction in this condition.
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INTRODUCTION
Graves’ orbitopathy (GO) is the most common extra-
thyroidal manifestation of Graves’ disease (GD), occurring in
25–50% of patients with the disease (1,2). GO may occur
during or after the onset of hyperthyroidism and less
frequently, in euthyroid or hypothyroid patients. The close
clinical association between immunogenic hyperthyroidism
and orbitopathy suggests that the antigen responsible for
these diverse conditions may be shared by the thyroid gland
and orbital tissues (3). The disease has a self-limited active
phase that usually lasts 18 to 24 months and abates slowly,
followed by an inactive (static) phase (4). In the active phase,
inflammation, the accumulation of glycosaminoglycans and
an increased fat content determine the tissue expansion
within the relatively fixed space constraint of the bony orbit.
The diagnosis of GO is usually made clinically. The signs
and symptoms of active GO include lid retraction, proptosis,
conjunctival injection, chemosis, diplopia, corneal ulceration
and rarely, dysthyroid optic neuropathy (DON) (5). In the
chronic fibrotic phase, lid retraction, proptosis and restrictive
strabismus are the most common findings. Patients with GO
pose few diagnostic difficulties when these characteristic
ocular findings occur concomitantly with the thyroid disease.
However, when unilateral or inconclusive ocular features
occur in the absence of objective evidence of thyroid
dysfunction, GO can be difficult to diagnose (6).
Among the ocular features, eyelid retraction plays a major
role in the clinical diagnosis of the disease. According to
Bartley and Gorman’s diagnostic criteria (7), GO may be
diagnosed when eyelid retraction occurs in association with
exophthalmos, DON or extraocular muscle involvement. If
eyelid retraction is absent, positive laboratory tests are
required for diagnosis.
Affecting 4–8% of patients, DON has long been recognized
as the most feared complication of GO (8,9). Although
inflammatory (10–12) and ischemic (13) mechanisms have
been suggested, the most widely accepted explanation is the
mechanical compression of the optic nerve at the orbital apex
by the enlarged extraocular muscles (14). Because DON may
present a wide range of symptoms and signs, its diagnosis
depends on several clinical features, including decreased
visual acuity (VA), abnormal visual fields (VF), impaired
color and brightness perception, delayed visually evoked
potentials, afferent pupillary defects and edema or atrophy of
the optic nerve head (9). Patients with GO are often assumed
to have DON when one of these features is present and no
other cause for the defect is observed, but visual impairment
in GO is not uncommonly related with other factors (15).
Consequently, in GO patients, direct optic nerve function
testing can yield misleading results that occasionally make it
difficult to distinguish probable from definitive DON.
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Although the diagnosis of GO and DON is based primarily
on clinical signs from laboratory test results suggestive of
thyroid dysfunction and autoimmunity, imaging studies,
such as computed tomography (CT), magnetic resonance
imaging (MRI), ultrasonography (US) and color Doppler
imaging (CDI), can also be extremely important in both the
diagnosis and clinical or surgical follow-up. Imaging studies
can verify possible extraocular muscle involvement as part of
the diagnostic workup and may help distinguish the early
acute inflammatory stage from the fibrotic, inactive stage of
the disease (16). Finally, imaging studies of patients prone to
developDONmake the timely diagnosis and treatment of the
condition possible, avoiding permanent visual loss (17). The
purpose of this paper is therefore to review imaging
modalities that can aid in the diagnosis and management of
GO, with a special emphasis on the diagnosis of GO-related
optic nerve dysfunction.
Imaging modalities in Graves’ orbitopathy
Computed tomography (CT). CT can distinguish normal
structures from abnormal structures of different tissue density
based on their differing X-ray absorption properties. Fat and
water have low densities and therefore appear black on CT
images, in contrast to denser muscles, the optic nerve and
bony structures. Effectively acting as a natural contrast
medium, the presence of orbital fat allows good spatial and
density resolution of orbital structures (18). The tissue di-
fferences inherent in the orbit obviate the need for intravenous
contrast in many situations. After digital recording, the data
are converted via an arithmetic procedure into different
grayscales. Compared with isodense tissues (e.g., the brain),
tissues with high absorption values (e.g., bone) appear
hyperdense, whereas tissues with low absorption values
(e.g., water or fat) appear hypodense (4).
The introduction of spiral CT in the early 1990s repre-
sented a fundamental evolutionary step in the development
and ongoing refinement of CT imaging techniques. Con-
tinuous scanning of anatomical regions within a short time
frame yields compelling results, and the technology has
been shown to offer undisputable advantages in lesion
detection and isotropic spatial resolution (19). Individual
volume elements obtained from axial slices can be refor-
matted in any plane to produce coronal, sagittal, paraxial or
parasagittal oblique images. Unlike direct coronal scans,
sagittal and coronal reformations avoid high spatial
frequency artifacts from dental appliances and other metal
implants. Multiplanar reformations make it possible to view
a lesion in the optimal anatomic plane and determine its
location relative to contiguous orbital, bone, sinus and
central nervous system structures. The advent of multi-
detector computed tomography (MDCT) has improved
image quality and resolution by enabling the simultaneous
acquisition of multiple slices and faster gantry rotation (20).
Magnetic resonance imaging (MRI). Hydrogen nuclei
with an odd number of nucleons (protons and neutrons)
behave as small magnets or dipoles. Protons are ubiquitous,
and their resonance is the basis of MRI techniques (21). MRI
captures signals from the free-moving protons in tissue as
the protons return to their primary position in a high
magnetic field after deflection by a frequency pulse. When
an organ is placed in a magnetic field, there is a net
alignment of protons. Radio-frequency excitation reverses
the polarity of some of these hydrogen nuclei, raising their
level of energy. When the excitation stops, the protons return
to their original polarity, emitting a measurable amount of
energy. This process is called T1 relaxation (T1), and it is best
measured just after the radio-frequency excitation is stopped.
Radio-frequency excitation also initiates a uniform syn-
chronous precession, or spin, in the protons. Following the
excitation, the spinning subsides at different rates in different
molecular environments. The energy emission measured
from this process is called the T2 relaxation time (T2) (4). T1
and T2 can be used to distinguish between tissue types with
different proton densities. T1-weighted (T1w) images may be
used to evaluate anatomic structures, whereas T2-weighted
(T2w) images provide useful information about tissue com-
position. Additionally, certain T1 or T2 weights achieved by
applying special pre-pulses can be used to distinguish water
from fat.
Ultrasonography (US). Grayscale US has been used in
ophthalmology since the late 1950s. Standardized diagnostic
US for eye diseases is performed using high frequencies
(optimally 8 MHz) and small wavelengths to visualize small
ocular structures. Both A-scan and B-scan transocular
echograms are performed. A-scans are used to assess the
tissue characteristics based on the reflected acoustic waves.
This technique is particularly sensitive for identifying the
thickening or thinning of the muscles and for differentiating
underlying pathologies. The reflectivity of the extraocular
muscles may change as a result of tissue edema and cellular
infiltration (4). It is easier to visualize the orbital structures
using a B-scan, especially when the examination is not
performed by an experienced ultrasonographer. B-scans are
very helpful in topographic evaluations and when
determining whether individual recti muscles are enlarged.
The main advantages of orbital US are its low cost and the
lack of ionizing radiation. Additionally, in experienced
hands, a relatively short examination time is adequate to
monitor the anterior and midorbital therapeutic response.
The main disadvantages of US are the high intra- and
interobserver variability, the inability to adequately visua-
lize the orbital apex and the poor quality of the anatomic
information obtained of the bony orbital walls compared
with the information provided by CT and MRI (18).
Color Doppler imaging (CDI). CDI is an ultrasonic
imaging modality that allows the assessment of blood flow
in real time on a grayscale B-mode background. The technique
was first described in 1979 (22) and is well tolerated and
widely used as a noninvasive imaging technique in many
medical specialties. More recently, CDI has been introduced as
an adjunct to the clinical examination and cross-sectional
imaging for evaluating several pathological conditions in the
orbit. Although the topography of the orbital structures can be
evaluated with grayscale US, CDI makes it possible to assess
the blood flow in the orbital vessels and detect changes in the
perfusion of the orbital arteries and veins (23).
CDI produces conventional grayscale US images together
with information about the direction and velocity of the
blood flow. The velocity data are superimposed onto the
grayscale image by assigning a color scale to the data (24).
The indications for and uses of CDI in ophthalmology are still
evolving but primarily include vascular disorders. CDI has
been used to investigate changes in blood flow parameters in
disorders such as anterior ischemic optic neuropathy, central
artery occlusion, central retinal vein occlusion, glaucoma,
diabetes mellitus, ocular ischemic syndrome, uveitis and
endophthalmitis. In orbital abnormalities, CDI is well suited
for the evaluation of cavernous-carotid fistula, orbital varix,
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orbital tumors, orbital cellulitis and orbital inflammatory
conditions (24,25).
The major blood supply to the orbit is through the
ophthalmic artery (OA), and the major venous drainage is
through the superior ophthalmic vein (SOV) to the cavernous
sinus. CDI can be used to assess the OA and its branches,
such as the SOV and inferior ophthalmic vein. The CDI
assessment of patients with GO is of great value because
studies have shown that venous congestion plays a sig-
nificant role in the pathogenesis of the disease (26).
Imaging studies for diagnosing GO and defining
disease activity
Imaging studies can be helpful in establishing the dia-
gnosis of GO because they provide objective morphological
findings of the orbital structures. Based on such studies
(especially MRI and CT), it is possible to establish the degree
of extraocular muscle and orbital fat enlargement, exclude
coexisting orbital pathology, clarify a confusing clinical
picture, and perform surgical planning (12). A CT scan with
positive findings is included in many sets of diagnostic
criteria for GO (7,27–30).
GO presents an unusual imaging pattern. The extraocular
muscles appear to be the primary area of orbital involvement.
Despite attempts to establish normative measurements (31–
34), the assessment of muscle enlargement is often subjective
and requires comparison with the opposite orbit or prior
qualitative experience. Patients with GO usually present
symmetrical, multiple extraocular muscle enlargement in
both orbits, although asymmetrical muscle involvement can
occur. However, true unilateral orbital involvement is
uncommon, occurring in only 6 to 10% of patients (35). The
muscles most frequently affected are the medial and inferior
recti (Figure 1).
In a series of 116 CT scans of a heterogeneous population
of patients with GO in different stages of the disease, 85% of
the patients displayed definitive enlargement of the
extraocular muscles (36). The inferior and medial recti were
involved in 77% and 75% of the cases, respectively, and
were the most severely enlarged. The lateral (51%) and
superior (50%) recti were involved less frequently and less
severely. However, a later study found similar levels of
enlargement in all four major muscle groups (32). In another
CT scan study involving 349 thyroid patients, the inferior,
medial, superior and lateral recti were enlarged in 43%,
38%, 29%, and 16% of the cases, respectively. Two or more
muscles were enlarged in 70% of the patients with ocular
involvement (37).
Unlike in patients with orbital myositis or idiopathic
orbital inflammation, the evidence of muscle involvement in
patients with GO is usually limited to the nontendinous
portion of the muscle. Additionally, the extraocular muscles
in GO appear to be enlarged in a fusiform fashion, with sharp
borders (38). However, atypical cases with tendon involve-
ment and blurred muscle margins have been described
(31,39–41).
In the evaluation of the extraocular muscle characteristics
in GO, CT, and MRI are the preferred imaging procedures,
although US may also be useful (42). In clinical practice, US
may conveniently be used to measure the extraocular
muscles and exclude other diseases. However, although
some authors have used US to evaluate muscle size, the
technique has been found to have limited accuracy and add
no new information to the knowledge obtained from CT and
MRI studies (37,43,44).
Although the extraocular muscles have been described as
the ‘‘shock organ’’ of GO (31), many studies suggest that
expansion of the orbital fat compartment also represents a
major component of the disease process (45,46). In GO,
although some affected orbits are characterized by prominent
extraocular muscle enlargement, other orbits display mild
or no extraocular muscle involvement, occasionally with
clearly increased adipose tissue volume. Imaging studies can
distinguish these clinical differences (Figure 2). Consequently,
some reported diagnostic criteria for GO include the ob-
servation of orbital fat augmentation in CT images (28,47). The
observation of exophthalmos in patients with abnormally
Figure 1 - Coronal CT scans from two patients with Graves’
orbitopathy. A) Patient with symmetric enlargement of the
extraocular muscles in both orbits. B) Patient with asymmetric
involvement of the extraocular muscles.
Figure 2 - Axial CT scans from two patients with Graves’
orbitopathy. A) Patient with prominent enlargement of the
medial and lateral recti muscles. B) Patient with severe proptosis
of both orbits with clear fat tissue augmentation and no
extraocular muscle involvement.
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increased orbital adipose tissue is suggestive of GO, but
obesity and Cushing’s disease should also be considered (48).
GO is associated with a wide spectrum of radiological
findings in addition to extraocular muscle and fat tissue
enlargement, as described in the literature (36,49,50). CT
findings may include bone changes, especially in the lamina
papyracea of the ethmoid, with bowing resulting from
muscle pressure. Lacrimal gland displacement and enlarge-
ment, exophthalmos, anterior soft tissue swelling and super-
ior optic vein dilatation may also be observed in imaging
studies, but these are unspecific findings that do not support
the diagnosis of GO (32,51,52).
CT is generally the preferred imaging modality for the
diagnosis of patients with GO because of its ability to
visualize bone and soft tissues in the orbit. CT also aids the
evaluation of the orbital walls, sinus and orbital elements in
orbital decompression planning. Compared with MRI, CT is
less expensive and faster to perform; however, CT is less
efficient in the evaluation of soft tissue changes. Additionally,
MRI can reveal details that may be important in the
assessment of disease activity.
In addition to their importance in the diagnosis of GO,
imaging studies can aid the evaluation of inflammatory
disease activity. Changes observed with CT in sequential
measurements of the extraocular muscles may be related to
clinical activity; muscular involvement occurs early in GO
and subsides together with other clinical signs (53).
Nevertheless, MRI is preferred for studies assessing disease
activity because of its better performance in the evaluation
in soft tissues.
MRI estimates disease activity based on the water content
of the tissues. In GO, strongly T2-weighted and fat-su-
ppressed images obtained using the turbo inversion recovery
magnitude (TIRM) and short tau inversion recovery (STIR)
sequences have been shown to be useful in detecting
extraocular muscle edema (54). To differentiate active from
inactive GO, inflammatory edema of the extraocular muscles
must be distinguished from fibrous end-stage disease with
fatty degeneration using the T2 relaxation time, which is
shorter for fibrous tissue than for inflammatory tissue
(Figure 3) (55). However, edema is not always correlated
with disease activity because edema can also be the result of
both active inflammation and reduced venous outflow in
patients with fibrotic disease. Some studies have shown that
in T1w images, when gadolinium is combined with fat
saturation techniques, it is possible to distinguish inflamma-
tory edema from congestive venous outflow in burned-out
disease (Figure 4) (55,56). Non-fat-saturated T1w images are
also useful in the detection of fatty muscle degeneration.
These fatty or fibrotic muscle changes display no contrast
enhancement on matched fat-saturated T1w images.
In the management of GO, it is of great importance to
estimate the disease activity when selecting those patients
most likely to respond to immunosuppressive treatment.
Clinical activity scales, such as the clinical activity score
(CAS) described and validated by Mourits and the
Amsterdam orbitopathy group (57) and VISA classification
described by Dolman and Rootman (58), can be very helpful
in assessing disease activity. Although it might be assumed
that the combination ofMRI studies and clinical scoreswould
improve diagnostic accuracy, the results have been conflict-
ing. Some researchers have found no clear correlation
between MRI findings and CAS indexes (54,59,60), perhaps
because of the great variability in CAS scores between
observers or because only the extraocular muscles, and not
the inflamed orbital fat, were assessed. However, other
researchers have reported significant positive correlations
(61). Despite the controversy, MRI appears to be useful for
monitoring the response to treatment using measurements
such as the signal intensity (SI) and signal intensity ratio
(SIR).
The use of US has also been proposed for evaluating
disease activity. Prummel et al. (62) demonstrated ex-
traocular muscle reflectivity changes in the inflammatory
phase of GO, suggesting that US is a reliable tool for the
determination of disease activity. In the active phase, the
extraocular muscles have a lower internal reflectivity,
presumably due to edema, whereas in end-stage disease,
the muscles tend to show irregular high reflectivity from the
echogenic fibrotic scar tissue. However, not all studies have
found a correlation between CAS and US reflectivity (59,63).
Moreover, US is believed to provide less comprehensive
information on the extraocular muscles and inflammation
than MRI. It should also be noted that the adequate
Figure 3 - Coronal STIR MR image showing a bright signal from
the superior oblique muscles and inferior, medial and superior
recti muscles in both orbits in a patient with active Graves’
orbitopathy.
Figure 4 - Coronal T1-weighted MR images from a patient with
active Graves’ orbitopathy. A) Image showing enlargement of
the extraocular muscles without fatty degeneration. B) Fat-
suppressed and gadolinium-enhanced image showing a bright
signal from the inferior, medial and superior recti muscles.
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measurement of muscle reflectivity requires standardized
A-wave US equipment and an experienced examiner.
CDI has also been used as a tool for diagnosing GO and
assessing disease activity. Several studies have compared the
orbital blood flow in GO patients and control subjects
(25,64,65), as well as in patients with different clinical forms
of GO (66). Benning et al. (64) found that the flow velocity in
the right ophthalmic artery wasmuch greater in subjects with
clinically active GO than control subjects. This finding was
also reported by Alp et al. (25), which supports the assu-
mption that orbital inflammation increases orbital blood
flow. The research in this area is promising; Monteiro et al.
(26) recently compared the CDI findings from orbits with the
active form of the disease with findings from the same orbits
after (primarily surgical) treatment and found a significant
difference.
Finally, patients with GO may be diagnosed using
octreotide scintigraphy (octreoscan). Octreotide is a soma-
tostatine (SM) analogue labeled with indium, a substance
that has been used to localize tumors with membrane
receptors for SM. Based on the assumption that orbital
lymphocytes express SM receptors during the active phase
of GO, a high uptake of the radiolabelled octreotide may be
correlated with orbital inflammation and active disease
(67,68). A positive orbital octreoscan could be useful in the
assessment of disease activity in GO; however, the fact that
the technique is expensive, non-specific and associated with
a non-negligible radiation burden restricts its clinical
application (4).
Imaging studies for the diagnosis of dysthyroid
optic neuropathy
Computed tomography (CT). Several studies have shown
that certain CT scan parameters increase the suspicion of
DON. Although the stretching of the optic nerve by the
increased orbital fat associated with axial proptosis is in rare
cases considered a possible pathogenic mechanism for
developing optic neuropathy (69), the most important me-
chanism is orbital apical crowding by the enlarged
extraocular muscles (9,14,17,32,52,70–73). Because the presen-
ce of apical crowding in CT images is strongly correlated with
DON in GO, many CT studies have proposed indexes
designed to objectively detect DON in several different
manners.
In a pioneer study based on linear measurements of the
extraocular muscles and bony orbit, Barrett (52) described a
simple method of quantifying extraocular muscle impinge-
ment on the optic nerve space. Using a reformatted scan
halfway between the posterior globe and orbital apex, the
vertical diameter of the superior rectus muscle–levator
muscle complex (A) and inferior (B) rectus muscles, as well
as the orbital height (C), were measured with a ruler along a
horizontal line through the optic nerve. The vertical
muscular index was expressed as the percentage of the
orbital height occupied by the superior rectus muscle–
levator muscle complex and inferior rectus muscles ([A+B/
C]6100) (Figure 5). In the same manner, the transverse
dimensions of the medial and lateral rectus muscles and
orbital width were measured to determine the horizontal
muscle index ([D+E/F]) (Figure 5). The greater of the two
ratios was considered the muscle index. The study showed
that a muscle index of 67% or greater indicated compressive
neuropathy with a diagnostic sensitivity of 67%, although
no patient with NOD had a muscle index of less than 50%.
In a recent study using MDCT imaging, this linear index
displayed the best combination of sensitivity and specificity
(79% and 72%, respectively) at a muscle index of 60% (71).
Barrett’s index was found by other authors to provide
satisfactory performance in the detection of DON (17,73).
The subjective assessment of apical crowding based on
single coronal images, as described by Nugent et al.(32) and
others (9,17,70,73,74), has also been shown to a be good
predictor of DON. In these studies, a coronal image at the
apex is subjectively graded according to the severity of the
muscle crowding. According to this method, the effacement
of the perineural fat is graded 0 (none), 1 (up to 25%), 2 (25–
50%), or 3 (greater than 50%) (Figure 6) (32). Nugent et al.
found severe apical orbital crowding (grade 3) in 12 of 18
orbits with DON but in only 16 of 124 orbits without DON
(32). Neigel et al. graded 79.2% of the orbits with DON and
12.9% of the orbits without DON as having moderate or
severe crowding (9). Birchall et al. found severe apical
crowding to be a good predictor of DON, with a sensitivity
of 62% and specificity of 91% (74). A recent multicenter
study found apical muscle crowding in 49 of 56 orbits with
DON (70). In another study, severe optic nerve crowding
was retrospectively noted in 80% of the orbits (16 of 20) with
optic neuropathy and 29% of the orbits without DON (10 of
34). No orbits with optic neuropathy had less than grade 2
evidence of optic nerve crowding (17). However, although it
appears clear that the Nugent’s apical crowding score is
useful for raising suspicion of DON, the score does not
provide a clear definition of the position along the orbit
where the coronal plan should be taken to determine the
score, and there is no clear differentiation between grade 1,
Figure 5 - Schematic representation of the method for calculat-
ing Barrett’s muscle index. The vertical index was calculated by
the sum of the vertical muscle diameters (A and B) divided by the
height of the orbit (C). The horizontal index was calculated by
dividing the sum of the horizontal muscle diameters (D and E) by
the horizontal diameter of the orbit (F).
Figure 6 - Coronal CT scan showing orbits with apical crowding
due to enlarged extraocular muscles. The right orbit shows
effacement of the perineural fat up to 25% of the circumference
(grade 1 in Nugent’s score); the left orbit shows no effacement of
the perineural fat (grade 0).
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2, and 3 orbital crowding. More recently, the objective
quantification of apical orbital crowding based on square
area measurements was shown to be a more efficient
diagnostic tool than subjective quantification. In this study,
the best-performing index was highly efficient at detecting
DON, with a sensitivity of 91.7% and specificity of 90.0%
(75).
Chan et al. (73) highlighted the importance not only of
extraocular muscle enlargement but also the role of the bony
orbit and its usefulness as a predictor of DON. The bony orbit
capacity was quantified using standardized orbital angles on
axial scans. The study showed that these measurements were
independent predictors of DON and that narrower orbits
were more susceptible to develop DON. The authors also
calculated an index of orbital muscular crowding in
combination with lateral and medial orbital wall angles that
had a 73.3% sensitivity and 90% specificity.
Birchall et al. (74) found intracranial fat prolapse through
the superior orbital fissure to be a predictor of DON, but
later studies have not confirmed the usefulness of this
parameter (70,73). Other CT features have been tested as
indicators of DON, including lacrimal gland displacement,
exophthalmos, superior optic vein dilatation, and single
muscle measurements, yielding conflicting and mostly
discouraging results (9,17,32,52,74,76).
Although linear or square measurements have proved
helpful in diagnosing DON, the estimation of the orbital
apex crowding based on volumetric estimates of structures
could potentially improve the ability to detect DON.
Feldon et al. (14,77) have used volumetric estimation of
the orbital content to investigate the risk of developing
DON in GO. Previously, such estimates involved cumber-
some measurements of the extraocular muscles, but recent
advances in MDCT have made volumetric estimates of
orbital structures readily available at a workstation (78). In
a recent study, orbital crowding indexes were for the first
time calculated based on the volumetric analysis of CT
images. The orbital fat and muscle volumes were estimated
based on their different attenuations in Hounsfield units
from measurements from the anterior orbital rim up to the
optic foramen. Based on these measurements, two volu-
metric indexes of orbital muscle crowding were calculated:
one based on axial scans of the entire orbit and another
based on coronal scans of the orbital apex. Both indexes
were efficient in predicting DON, especially the index
limited to the orbital apex (with 92% sensitivity and 86%
specificity) (79).
Magnetic Resonance Imaging (MRI). Very few MRI
studies have directly assessed DON. Dodds et al. (80)
assessed DON in a high-resolution MRI study in which
they compared the diameter of the optic nerve at seven
different positions from the eyeball to the pre-chiasmal
region in three groups (control, GO with DON, and GO
without DON). The optic nerve diameter was significantly
smaller in the group with DON. However, the overall
reduction was not substantial, and there was considerable
overlap between the control subjects and patients with DON.
The authors admitted that despite the observed reduction in
the optic nerve size in the DON group, neural compression
could not be shown to be the pathogenic mechanism
underlying the nerve dysfunction, but they found
mechanical compression of the optic nerve to be the most
plausible explanation. Alternatively, DON might be caused
by vascular compression or some other unidentified
mechanism. The authors also observed reductions in the
optic nerve diameter in the absence of enlarged extraocular
muscles, suggesting that the compression results from
increases in the intraorbital pressure due to the increased
fat volume.
Although CT is excellent for outlining bone details, MRI
provides better soft tissue detail and is useful for evaluating
the extraocular muscles, optic nerve and fat. Therefore,
further studies are necessary to better investigate the ability
of MRI to detect DON, alone or in association with CT.
Ultrasonography and color Doppler imaging. In some
studies, US has been used to attempt to identify the
presence of DON. One study has suggested that US can
detect DON-related enlargement of the subarachnoid space
of the optic nerve, but this is apparently only rarely noted
(4). The evaluation of the venous flow can also be useful.
Monteiro et al. (66) reported that patients with congestive
orbitopathy and predominantly myogenic fibrotic GO
experience a significant reduction in the SOV flow, match-
ing reports from other authors (81) and supporting the idea
that orbital congestion due to extraocular muscle enlarge-
ment can reduce orbital venous drainage. Because DON is
known to be related to orbital apex crowding, the existence
of severe venous stasis in the orbits possibly reflects a stage
in its development. Although both US and CDI can
produce findings suggestive of DON, systematic studies
differentiating congestive cases with DON from cases
without DON are needed to determine the usefulness of
these methods.
Although the diagnosis of GO and DON still relies heavily
on clinical data, recent decades have seen outstanding
developments in orbital imaging techniques. Important
imaging studies have led to the emergence of new perspec-
tives in the diagnosis and treatment of GO, which constitute
the main topic of this review.
CT remains the main imaging modality in Graves’
disease. CT can be used to establish the degree of ex-
traocular muscle and orbital fat enlargement, clarify a con-
fusing clinical picture and aid surgical planning. Fur-
thermore, CT can be of great help in the detection of DON
using linear, area or volumetric indexes of orbital apex
crowding. However, CT provides little information on the
disease activity, except through the observation of changes
in sequential studies.
MRI can also be used to diagnose GO. However, the
ability of MRI to provide evidence for DON has still not
been explored, perhaps due to the difficulty of estimating
the orbital bone volume and thereby determining the
amount of orbital apex crowding. However, due to its
greater ability to differentiate soft tissues, MRI has become a
useful adjunct in imaging studies of GO patients when GO-
related muscle involvement must be differentiated from
other orbital conditions. Additionally, progressive technical
refinements will likely enhance its usefulness, especially in
the assessment of GO activity upon diagnosis and during
treatment.
US is a well-established, accessible and low-cost techni-
que widely used to detect extraocular muscle enlargement.
However, the inability to perform an accurate evaluation of
the orbital apex compared with CT or MRI has reduced the
importance of US in the diagnosis and management of GO.
Although it is still in an early developmental stage, CDI may
become useful in the management of GO because CDI is the
technique that best evaluates orbital venous congestion, a
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possible contributing factor during the active congestive
stage of GO.
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